Transgenic Beta Cells Expressing CXCL12 to Resist Immune Destruction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for beta cell transplantation in diabetes, particularly type 1 diabetes, face challenges such as immune cell destruction, low survival rates, and the need for repeated surgeries due to encapsulation failures, which are not adequately addressed by existing encapsulation technologies.
Innovation Solution
Development of transgenic human beta cells that express a fugetactic agent like CXCL12 or CXCL13, making them resistant to human immune cells and capable of insulin production in hyperglycemic environments, with the cells being either autologous or allogeneic and potentially senescent to prevent cancer formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If beta cells are transplanted to treat diabetes, then insulin production is restored, but immune cells destroy the transplanted beta cells
Solution Approach 1:
The patent introduces an intermediary substance (fugetactic agent such as CXCL12 or CXCL13) that is not directly involved in insulin production but mediates the interaction between beta cells and immune cells. This agent creates a chemical barrier that repels immune cells while allowing the beta cells to maintain their insulin-producing function, thus resolving the contradiction between productivity and reliability
Solution Approach 2:
The patent applies preliminary anti-action by pre-treating the beta cells with fugetactic agents before transplantation. This preliminary treatment establishes a protective mechanism that prevents immune cell attack before it occurs, allowing the beta cells to survive and continue producing insulin without being destroyed by the host immune system
2Reliability
If encapsulation technology is used to protect beta cells, then immune cell destruction is reduced, but repeated surgeries are required due to encapsulation failures
Solution Approach 1:
The patent enables beta cells to self-protect by endogenously expressing fugetactic agents. This self-service mechanism eliminates the need for external encapsulation structures that require surgical intervention for replacement. The beta cells autonomously produce the protective chemical barrier, thereby preventing immune destruction without requiring repeated surgeries
Solution Approach 2:
The patent extracts the protective function from the encapsulation structure and transfers it to the beta cells themselves. By taking out the need for physical encapsulation and implementing chemical protection through fugetactic agents, the system eliminates the requirement for repeated surgical interventions while maintaining reliable protection from immune destruction
3Quantity of substance
If stem cells are used to generate beta cells, then cell supply is increased, but cancer formation risk increases
Solution Approach 1:
The patent applies parameter changes by modifying the genetic state of stem cells to express fugetactic agents. This genetic modification alters the cellular parameters to include immune protection without requiring excessive cell proliferation. The changed parameter (expression of fugetactic agent) provides both protection and control mechanisms that reduce cancer risk while maintaining adequate cell supply
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transgenic beta cells effectively resist immune destruction and maintain insulin production, potentially eliminating the need for repeated surgeries and improving the longevity and efficacy of beta cell transplantation.
Implementation Method 1
The genetically modified (transgenic), human beta cells express a fugetactic amount of a fugetactic agent thereby imparting protection against human mononuclear immune cells
Implementation Method 2
capable of insulin production in hyperglycemic environments
Data Source
AI summary
Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.